

*Cited in PCT search report*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/705, A61K 38/16, G01N 33/68, C12Q 1/68, C07K 16/28</b>		A1	(11) International Publication Number: <b>WO 99/29849</b>  (43) International Publication Date: <b>17 June 1999 (17.06.99)</b>
(21) International Application Number: <b>PCT/US98/25565</b>		(74) Agents: <b>BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</b>	
(22) International Filing Date: <b>2 December 1998 (02.12.98)</b>			
(30) Priority Data: <b>08/988,876 11 December 1997 (11.12.97) US</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application <b>US 08/988,876 (CIP) Filed on 11 December 1997 (11.12.97)</b>			
(71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</b>		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US).</b>			

(54) Title: **G-PROTEIN COUPLED RECEPTORS ASSOCIATED WITH IMMUNE RESPONSE**

(57) Abstract

The invention provides two human G-protein coupled receptors associated with immune response (GRIR) and polynucleotides which identify and encode GRIR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of GRIR.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## G-PROTEIN COUPLED RECEPTORS ASSOCIATED WITH IMMUNE RESPONSE

### TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of two new G-protein coupled receptors associated with immune response and to the use of these sequences in the diagnosis, treatment, and prevention of diseases associated with cell proliferation and cell signaling.

### BACKGROUND OF THE INVENTION

10 G-protein coupled receptors (GPCR) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, e.g., dopamine, epinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin; for lipid mediators of inflammation such 15 as prostaglandins, platelet activating factor, and leukotrienes; for peptide hormones such as calcitonin, C5a anaphylatoxin, follicle stimulating hormone, gonadotropin releasing hormone, neurokinin, oxytocin, and thrombin; and for sensory signal mediators, e.g., retinal photopigments and olfactory stimulatory molecules.

15 The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. The N-terminus interacts with ligands, the disulfide bridge interacts with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate 20 second messengers such as cyclic AMP, phospholipase C, inositol triphosphate, or ion channel proteins. The most conserved parts of these proteins are the transmembrane regions and the first two cytoplasmic loops. A conserved, acidic-Arg-aromatic triplet 25 present in the second cytoplasmic loop may interact with the G proteins. The consensus pattern.

25 [GSTALIVMYWC]-[GSTANCPDE]-{EDPKRH}-x(2)-[LIVMNQGA]-x(2)-[LIVMFT]-[GSTANC]-[LIVMFYWSTAC]-[DENH]-R-[FYWCSH]-x(2)-[LIVM] is characteristic of 30 most proteins belonging to this superfamily. (Watson, S. and S. Arkinstall (1994) The G-

protein Linked Receptor Facts Book, Academic Press, San Diego, CA; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego, CA.)

Odorant receptors are members of a multigene family primarily responsible for transmission of volatile chemical signals from the environment through the olfactory neuron to cortical regions of the brain. Odorant receptors have been detected in olfactory epithelium of many mammalian species (e.g., dog, rat, mouse, and human), and a homologous family of receptors is expressed in human testes where it is responsible for sperm chemotaxis. (Parmentier, M. et al. (1992; Nature 355:453-455.)

The rat olfactory protein is a member of the odorant receptor family, and one of the first molecules to be used to investigate the molecular basis of odor recognition. (Buck L. and R. Axel (1991) Cell 65:175-187.) The rat protein is 333 amino acids in length and has a glycosylation site at N<sub>5</sub>, a palmitoylation site at C<sub>306</sub>, and disulfide bonds at C<sub>97</sub> and C<sub>189</sub>. Homologous human olfactory receptors (OR) and OR pseudogenes have been cloned from mRNA and genomic DNA (Crowe, M.L. (1996) Gene 169:247-249).

Chemotactic receptors are important in immune responses. They are activated by chemokines, platelet activating factor (PAF), and proteases. These receptors are found on monocytes, lymphocytes, neutrophils, basophils, eosinophils, platelets and leukocytes of several mammalian species including guinea pig, rat, mouse, and human. Chemotactic receptors are widely expressed in peripheral tissues and are present in smooth muscle, lung, brain, liver, and endothelial cells.

Complement is produced in the liver, circulates in the blood and extracellular fluid, and stimulates cells to fight infections. Complement 5 (C5) is proteolytically cleaved to produce C5a and C5b whenever the complement system is activated. C5a is one of 13 plasma proteins responsible for clearing foreign particles and organisms from the blood. In addition, human C5a, a 74 amino acid peptide, functions as a chemoattractant for immune system cells.

The C5a receptor is a GPCR which is present on neutrophils, macrophages, and mast cells and is believed to interact with a Gq-/G11-protein to activate the phosphoinositol signaling pathway. The KIAA0001/C5a receptor is 338 amino acids long and has a N-glycosylation site at Asn3. (Nomura, N. et al. (1994) DNA Res. 1:27-35.)

Charlton, M.E. et al. (1997; Brain Res. 764:141-8) identified VTR 15-20, a GPCR of 305 amino acids from rat ventral tegmentum. The cDNA shares homology to several

orphan receptors, and the deduced protein demonstrates the specific regions conserved among the superfamily. VTR 15-20 is expressed throughout the mammalian nervous system and in cultured rat microglia and astrocytes. The highest levels of VTR 15-20 mRNA expression were detected in peripheral tissues and spleen. Based on cellular distribution, expression in brain and spleen, and regulation as the result of immune challenge and neuronal insult, VTR 15-20 appears to play a role in neuroimmune function.

The discovery of new G-protein coupled receptors associated with immune response and the polynucleotides encoding these receptors satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of diseases associated with cell proliferation and cell signaling.

### SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, G-protein coupled receptors associated with immune response, referred to collectively as "GRIR" and individually as "GRIR-1" and "GRIR-2." In one aspect, the invention provides a substantially purified polypeptide, GRIR, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3.

The invention further provides a substantially purified variant of GRIR having at least 90% amino acid identity to the amino acid sequences of SEQ ID NO:1 or SEQ ID NO:3, or to a fragment of either of these sequences. The invention also provides an isolated and purified polynucleotide sequence encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3.

Additionally, the invention provides a composition comprising a polynucleotide sequence encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a

fragment of SEQ ID NO:3. The invention further provides an isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3, as well as an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3.

The invention also provides an isolated and purified polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:4. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:4, as well as an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:4.

The invention further provides an expression vector containing at least a fragment of the polynucleotide sequence encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, or a fragment of SEQ ID NO:3, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide sequence encoding GRIR under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified GRIR having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, or a fragment of SEQ ID NO:3 in conjunction with a

suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, or a fragment of SEQ ID NO:3, as well as a purified agonist and a purified antagonist to the polypeptide.

5 The invention also provides a method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of GRIR.

10 The invention further provides a method for treating or preventing an immune response, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of GRIR.

15 The invention also provides a method for detecting a polynucleotide encoding GRIR in a biological sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence encoding the polypeptide comprising SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, or a fragment of SEQ ID NO:3 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding GRIR in the biological sample. In one aspect, the nucleic acids of the biological 20 sample are amplified by the polymerase chain reaction prior to the hybridizing step.

#### BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, 1C, 1D, and 1E show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of GRIR-1. The alignment was produced using 25 MacDNAsis PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

Figures 2A and 2B show the amino acid sequence alignments among GRIR-1 (364702; SEQ ID NO:1) and canine, rat and human olfactory receptors (g1314667, SEQ ID NO:5; g205814, SEQ ID NO:6; and g32086, SEQ ID NO:7, respectively).

30 Figures 3A, 3B, 3C, and 3D show the amino acid sequence (SEQ ID NO:3) and nucleic acid sequence (SEQ ID NO:4) of GRIR-2. The alignment was produced using MacDNAsis PRO™ software.

Figures 4A and 4B show the amino acid sequence alignments among GRIR-2

(1650519; SEQ ID NO:3), human KIAA0001 (g285995, SEQ ID NO:8); and rat VTR 15-20 receptor (g49443, SEQ ID NO:9).

Figures 5A and 5B show the northern analyses for GRIR-1 (SEQ ID NO:1) and GRIR-2 (SEQ ID NO:3) respectively.

5

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## DEFINITIONS

"GRIR," as used herein, refers to the amino acid sequences of substantially purified GRIR obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist," as used herein, refers to a molecule which, when bound to GRIR, increases or prolongs the duration of the effect of GRIR. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of GRIR.

5 An "allele" or an "allelic sequence," as these terms are used herein, is an alternative form of the gene encoding GRIR. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of 10 nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GRIR, as described herein, include those sequences with deletions, insertions, or substitutions of different nucleotides, 15 resulting in a polynucleotide the same GRIR or a polypeptide with at least one functional characteristic of GRIR. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GRIR, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence 20 encoding GRIR. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GRIR. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity 25 of GRIR is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

30 The terms "amino acid" or "amino acid sequence," as used herein, refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments", "immunogenic

fragments", or "antigenic fragments" refer to fragments of GRIR which are preferably about 5 to about 15 amino acids in length and which retain some biological activity or immunological activity of GRIR. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

5        "Amplification," as used herein, relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art. (See, e.g., Dieffenbach, C.W. and  
10      G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, pp.1-5, Cold Spring Harbor Press, Plainview, NY.)

15      The term "antagonist," as it is used herein, refers to a molecule which, when bound to GRIR, decreases the amount or the duration of the effect of the biological or immunological activity of GRIR. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of GRIR.

20      As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fa, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind GRIR polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the  
25      animal.

30      The term "antigenic determinant," as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense," as used herein, refers to any composition containing a nucleic acid sequence which is complementary to a specific nucleic acid sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

As used herein, the term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic GRIR, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity," as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence," as these terms are used herein, refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation, an aqueous solution, or a sterile composition. Compositions comprising polynucleotide sequences encoding GRIR or fragments of GRIR may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS), and other components (e.g., Denhardt's solution, dry milk,

salmon sperm DNA, etc.).

The phrase "consensus sequence," as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction, and resequenced, or which has been 5 assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW™ Fragment Assembly system (GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence.

As used herein, the term "correlates with expression of a polynucleotide" indicates 10 that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding GRIR, by northern analysis is indicative of the presence of nucleic acids encoding GRIR in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding GRIR.

A "deletion," as the term is used herein, refers to a change in the amino acid or 15 nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative," as used herein, refers to the chemical modification of GRIR, 20 of a polynucleotide sequence encoding GRIR, or of a polynucleotide sequence complementary to a polynucleotide sequence encoding GRIR. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it 25 was derived.

The term "homology," as used herein, refers to a degree of complementarity. There may be partial homology or complete homology. The word "identity" may substitute for the word "homology." A partially complementary sequence that at least 30 partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of

reduced stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% homology or identity). In the absence of non-specific binding, the substantially homologous sequence or probe will not hybridize to the second non-complementary target sequence.

"Human artificial chromosomes" (HACs), as described herein, are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance. (Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

The term "humanized antibody," as used herein, refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization," as the term is used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

As used herein, the term "hybridization complex" as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, polymers, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

"Inflammation" as used herein is interchangeable with "immune response", both terms refer to a condition associated with trauma, immune disorders, and infectious or genetic diseases and are characterized by production of cytokines, chemokines, and other signaling molecules which activate cellular and systemic defense systems.

The words "insertion" or "addition," as used herein, refer to changes in an amino

acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

The term "microarray," as used herein, refers to an array of distinct polynucleotides or oligonucleotides arrayed on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term "modulate," as it appears herein, refers to a change in the activity of GRIR. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GRIR.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to an oligonucleotide, nucleotide, polynucleotide, or any fragment thereof, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which are greater than about 60 nucleotides in length, and most preferably are at least about 100 nucleotides, at least about 1000 nucleotides, or at least about 10,000 nucleotides in length.

The term "oligonucleotide," as used herein, refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. As used herein, the term "oligonucleotide" is substantially equivalent to the terms "amplimers," "primers," "oligomers," and "probes," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA), as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA and RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell. (Nielsen, P.E. et al. (1993) Anticancer Drug Des.

30 8:53-63.)

The term "sample," as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acids encoding GRIR, or fragments thereof, or

GRIR itself may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA (in solution or bound to a solid support); a tissue; a tissue print; and the like.

As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein recognized by the binding molecule (i.e., the antigenic determinant or epitope). For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

As used herein, the term "stringent conditions" refers to conditions which permit hybridization between polynucleotide sequences and the claimed polynucleotide sequences. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

For example, hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C. Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30°C to 35°C. In particular, hybridization could occur under high stringency conditions at 42°C in 50% formamide, 5X SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured salmon sperm DNA. Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

The term "substantially purified," as used herein, refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution," as used herein, refers to the replacement of one or more amino

acids or nucleotides by different amino acids or nucleotides, respectively.

"Transformation," as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, and refers to cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of GRIR, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

#### THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors associated with immune response (GRIR), the polynucleotides encoding GRIR, and the use of these compositions for the diagnosis, treatment, or prevention of diseases associated with cell proliferation and cell signaling.

Nucleic acids encoding the GRIR-1 of the present invention were first identified in Incyte Clone 364702 from the prostate cDNA library (PROSNOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from Incyte Clones 605666 (BRSTTUT01) and 364702 (PROSNOT01).

In one embodiment, the invention encompasses a polypeptide comprising the

amino acid sequence of SEQ ID NO:1 as shown in Figures 1A, 1B, 1C, 1D and 1E. GRIR-1 is 326 amino acids in length and has two potential N glycosylation sites at N<sub>28</sub> and N<sub>88</sub>, and five potential phosphorylation sites at S<sub>90</sub>, S<sub>177</sub>, T<sub>243</sub>, S<sub>285</sub>, and S<sub>309</sub>. As shown in Figures 2A and 2B, GRIR-1 has chemical and structural homology with canine, rat and 5 human olfactory receptors (g1314667, SEQ ID NO:3; g205814, SEQ ID NO:4; and g32086, SEQ ID NO:5, respectively). In particular, GRIR-1 shares 45% identity with the canine OR, 44%, with the rat OR, and 42%, with the human OR. In addition, the hydrophobic transmembrane domains are fairly well conserved among these molecules. TM1 extends from about V<sub>49</sub> to about S<sub>73</sub>; TM2, from about P<sub>81</sub> to about P<sub>102</sub>; TM3, from 10 about M<sub>124</sub> to about C<sub>141</sub>; TM4, from about F<sub>163</sub> to about L<sub>182</sub>; TM5, from about I<sub>122</sub> to about V<sub>243</sub>; TM6, from about P<sub>261</sub> to about L<sub>277</sub>; and TM7, from about A<sub>289</sub> to about L<sub>309</sub>. The cysteines at C<sub>120</sub>, C<sub>147</sub>, C<sub>164</sub>, and C<sub>203</sub> are conserved across all four receptors. The 15 extracellular ligand binding domain from about nucleotide 712 to about nucleotide 783 is the most useful fragment of SEQ ID NO:2. Northern analysis (Figure 5A) shows the expression of this sequence in gastrointestinal, male reproductive, and muscle cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 38% with immune response.

Nucleic acids encoding the GRIR-2 of the present invention were first identified in Incyte Clone 1650519 from the prostate cDNA library (PROSTUT09) using a computer 20 search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:4, was derived from Incyte Clones 1649584, 1650519, and 1650566 (PROSTUT09); 1721996 (BLADNOT06), and 2731380 (OVARTUT04).

In one embodiment, the invention encompasses a polypeptide comprising the 25 amino acid sequence of SEQ ID NO:3 as shown in Figures 3A, 3B, 3C, and 3D. GRIR-2 is 358 amino acids in length and has five potential N glycosylation sites at N<sub>4</sub>, N<sub>25</sub>, N<sub>33</sub>, N<sub>72</sub> and N<sub>251</sub>; and nine potential phosphorylation sites at Y<sub>153</sub>, S<sub>236</sub>, S<sub>244</sub>, S<sub>245</sub>, S<sub>253</sub>, S<sub>278</sub>, S<sub>337</sub>, S<sub>343</sub> and Y<sub>352</sub>. As shown in Figures 4A and 4B, GRIR-2 has chemical and structural 30 homology to human KIAA0001 (g285995, SEQ ID NO:8); and rat VTR 15-20 (g49443, SEQ ID NO:9) GPCRs. Specifically, GRIR-2 shares 42% identity with KIAA0001 and 24% identity with the rat VTR15-20. In addition, the hydrophobic transmembrane domains are conserved among these molecules. TM1 extends from about V<sub>44</sub> to about W<sub>65</sub>; TM2, from about F<sub>78</sub> to about V<sub>99</sub>; TM3, from about T<sub>127</sub> to about V<sub>143</sub>; TM4, from

about T<sub>158</sub> to about L<sub>174</sub>; TM5, from about V<sub>207</sub> to about C<sub>225</sub>; TM6, from about I<sub>254</sub> to about S<sub>275</sub>; and TM7, from about E<sub>297</sub> to about C<sub>318</sub>. The cysteine at C<sub>114</sub> is conserved across all three receptors. The most useful fragment of SEQ ID NO:4 encompasses the unique, extracellular ligand binding domain from about nucleotide 319 to about nucleotide 444.

5 Northern analysis (Figure 5B) shows the expression of this sequence in reproductive cDNA libraries. Approximately 83% of these libraries were associated with neoplastic disorders.

The invention also encompasses GRIR variants. A preferred GRIR variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at 10 least about 95% amino acid sequence identity to the GRIR amino acid sequence, and which contains at least one functional or structural characteristic of GRIR.

The invention also encompasses polynucleotides which encode GRIR-1 and GRIR-2. In a particular embodiment, the invention encompasses the polynucleotide sequences comprising the sequence of SEQ ID NO:2 and SEQ ID NO:4, which encode GRIRs.

15 The invention also encompasses a variant of a polynucleotide sequence encoding GRIR. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GRIR. A particular aspect of the invention encompasses a variant of SEQ ID NO:2 which has at least about 80%, more 20 preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to SEQ ID NO:2. A particular aspect of the invention encompasses a variant of SEQ ID NO:4 which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to SEQ ID NO:4. Any one of the polynucleotide variants described above can encode an amino acid 25 sequence which contains at least one functional or structural characteristic of GRIR.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GRIR, some bearing minimal homology to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible 30 variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GRIR,

and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GRIR and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring GRIR under appropriately selected conditions of stringency, it may be advantageous to produce  
5 nucleotide sequences encoding GRIR or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GRIR and its derivatives without  
10 altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GRIR and GRIR derivatives, or fragments thereof, entirely by synthetic chemistry. After  
15 production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GRIR or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable  
20 of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:2, or a fragment of SEQ ID NO:2, and SEQ ID NO:4, or a fragment of SEQ ID NO:4, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

25 Methods for DNA sequencing are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp., Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System marketed by  
30 GIBCO/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton. Reno, NV), Peltier Thermal Cycler

(PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding GRIR may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus. (Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) In particular, genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region. (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) The primers may be designed using commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN) or another appropriate program to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to 72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR. Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have

been size-selected to include larger cDNAs. Also, random-primed libraries are preferable in that they will include more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension 5 of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and a charge coupled device camera for detection of the emitted wavelengths. 10 Output/light intensity may be converted to electrical signal using appropriate software (e.g., Genotyper™ and Sequence Navigator™, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small 15 pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GRIR may be used in recombinant DNA molecules to direct expression of GRIR, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which 20 encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express GRIR.

As will be understood by those of skill in the art, it may be advantageous to produce ABBR-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can 25 be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GRIR encoding sequences for a 30 variety of reasons including, but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may

be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GRIR may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of GRIR activity, it may be useful to encode a chimeric GRIR protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the GRIR encoding sequence and the heterologous protein sequence, so that GRIR may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding GRIR may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of GRIR, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography. (Chiez, R.M. and Regnier, F.Z. (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (the Edman degradation procedure described in Creighton, T. (1983) Proteins, Structures and Molecular Properties, WH Freeman and Co., New York, NY.) Additionally, the amino acid sequence of GRIR, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active GRIR, the nucleotide sequences encoding GRIR or derivatives thereof may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GRIR and appropriate transcriptional

and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989; Molecular Cloning. A Laboratory Manual, ch. 4, 8, and 16-17, Cold Spring Harbor Press, Plainview, NY) and Ausubel, F.M. et al. (1995 and 5 periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, NY).

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GRIR. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

15 The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector (i.e., enhancers, promoters, and 5' and 3' untranslated regions) which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, 20 any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, La Jolla, CA) or pSport1™ plasmid (GIBCO/BRL), and the like, may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or 25 enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding GRIR, vectors based on SV40 or EBV 30 may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for GRIR. For example, when large quantities of GRIR are needed

for the induction of antibodies. vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding GRIR may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced. pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509), and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used. For reviews, see Ausubel (supra) and Grant et al. (1987; Methods Enzymol. 153:516-544).

In cases where plant expression vectors are used, the expression of sequences encoding GRIR may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV. (Takamatsu, N. (1987) EMBO J. 6:307-311.) Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews. (See, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.)

An insect system may also be used to express GRIR. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding GRIR may be cloned into a non-essential region of the virus, such as

the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of GRIR will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which GRIR may be expressed. (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227.)

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GRIR may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing GRIR in infected host cells. (Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GRIR. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding GRIR and its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular cell system used, such as those described in the literature. (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation,

glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding, and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, 5 HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long term, high yield production of recombinant proteins, stable expression is preferred. For example, cell lines capable of stably expressing GRIR can be transformed 10 using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the 15 selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase genes 20 (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase genes (Lowy, I. et al. (1980) Cell 22:817-23), which can be employed in *tk* or *apr* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dfr* confers resistance to methotrexate (Wigler, M. et al. 25 (1980) Proc. Natl. Acad. Sci. 77:3567-70); *npt* confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14); and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. 30 Acad. Sci. 85:8047-51.) Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$  glucuronidase and its substrate GUS, and luciferase and its substrate luciferin. These markers can be used not only to identify transformants, but

also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed.

5 For example, if the sequence encoding GRIR is inserted within a marker gene sequence, transformed cells containing sequences encoding GRIR can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GRIR under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene  
10 as well.

Alternatively, host cells which contain the nucleic acid sequence encoding GRIR and express GRIR may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane,  
15 solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

The presence of polynucleotide sequences encoding GRIR can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding GRIR. Nucleic acid amplification based assays  
20 involve the use of oligonucleotides or oligomers based on the sequences encoding GRIR to detect transformants containing DNA or RNA encoding GRIR.

A variety of protocols for detecting and measuring the expression of GRIR, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs),  
25 radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GRIR is preferred, but a competitive binding assay may be employed. These and other assays are well described in the art, for example, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, Section IV, APS Press, St  
30 Paul, MN) and in Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for

producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GRIR include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GRIR, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Pharmacia & Upjohn (Kalamazoo, MI), Promega (Madison, WI), and U.S. Biochemical Corp. (Cleveland, OH).

5            Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

10          Host cells transformed with nucleotide sequences encoding GRIR may be cultured under conditions suitable for the expression and recovery of the protein from cell culture.

15          The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GRIR may be designed to contain signal sequences which direct secretion of GRIR through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding 20 GRIR to nucleotide sequences encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity

25          purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences, such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA), between the purification domain and the GRIR encoding sequence may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing GRIR and a nucleic acid encoding 6 histidine residues preceding a

30          thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on immobilized metal ion affinity chromatography (IMAC; described in Porath, J. et al. (1992) Prot. Exp. Purif. 3: 263-281), while the enterokinase cleavage site provides a means

for purifying GRIR from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

Fragments of GRIR may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of GRIR may be synthesized separately and then combined to produce the full length molecule.

## 10 THERAPEUTICS

Chemical and structural homology exists among GRIR-1, and canine, rat and human olfactory receptors (g1314667, SEQ ID NO:5; g205814, SEQ ID NO:6; and g32086, SEQ ID NO:7, respectively). In addition, GRIR-1 is expressed in gastrointestinal, male reproductive, and muscle cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 38%, with immune response. Therefore, GRIR-1 appears to play a role in cell proliferation and cell signaling.

Chemical and structural homology exists among GRIR-2, human KIAA0001 (g285995, SEQ ID NO:8); and rat VTR 15-20 (g49443, SEQ ID NO:9) GPCRs. In addition, GRIR-2 is expressed primarily reproductive tissues. Approximately 80% of these libraries are associated with neoplastic disorders. Therefore, GRIR-2 appears to play a role in cell proliferation and cell signaling.

In one embodiment, an antagonist of GRIR may be administered to a subject to treat or prevent a neoplastic disorder. Neoplastic disorders may include, but are not limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector expressing the complement of the polynucleotide encoding GRIR may be administered to a subject to treat or prevent a neoplastic disorder including, but not limited to, those described above.

In an additional embodiment, an antagonist of GRIR may be administered to a

subject to treat or prevent an immune response. Immune responses may be associated with, but are not limited to: AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anaphylaxis, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, 5 bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, cystic fibrosis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, chronic granulomatous disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, 10 rheumatoid arthritis, scleroderma, sickle cell anemia, Sjögren's syndrome, systemic sclerosis, thalassemia, ulcerative colitis, Werner syndrome, and complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma.

15 In another embodiment, a vector expressing the complement of the polynucleotide encoding GRIR may be administered to a subject to treat or prevent an immune response including, but not limited to, those described above.

20 In one aspect, an antibody which specifically binds GRIR may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GRIR.

25 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

30 An antagonist of GRIR may be produced using methods which are generally known in the art. In particular, purified GRIR may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GRIR. Antibodies to GRIR may also be generated using methods that are well known in the art.

Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GRIR or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GRIR have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of GRIR amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GRIR may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques

described for the production of single chain antibodies may be adapted, using methods known in the art, to produce ABBR-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-11123.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837, and Winter, G. et al. (1991) Nature 349:293-299.)

10 Antibody fragments which contain specific binding sites for GRIR may also be generated. For example, such fragments include, but are not limited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse, W.D. et al. (1989) Science 254:1275-1281.)

15 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GRIR and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GRIR epitopes is preferred, but a competitive binding assay may also be employed. (Maddox, supra.)

20 In another embodiment of the invention, the polynucleotides encoding GRIR, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding GRIR may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding GRIR. Thus, complementary molecules or fragments may be used to modulate GRIR activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GRIR.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence complementary to the polynucleotides of the gene encoding GRIR. These techniques are described, for example, in Sambrook (*supra*) and in Ausubel (*supra*).  
5

Genes encoding GRIR can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof encoding GRIR. Such constructs may be used to introduce untranslatable sense or  
10 antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.  
15

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding GRIR. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix  
20 base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr,  
Molecular and Immunologic Approaches, pp. 163-177, Futura Publishing Co., Mt. Kisco,  
25 NY.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by  
30 endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GRIR.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene  
5 containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be  
10 prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GRIR. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA  
15 polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life.  
20 Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine,  
25 thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or  
30 by polycationic amino polymers may be achieved using methods which are well known in the art, such as those described in Goldman, C.K. et al. (1997; Nature Biotechnology 15:462-466).

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of GRIR, antibodies to GRIR, and mimetics, agonists, antagonists, or inhibitors of GRIR. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice,

potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, 5 and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may 10 be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or 15 binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be 20 formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable 25 lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. 30

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

5       The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

10      After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of GRIR, such labeling would include amount, frequency, and method of 15 administration.

15      Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

20      For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays of neoplastic cells, for example, or in animal models, usually mice, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

25      A therapeutically effective dose refers to that amount of active ingredient, for example GRIR or fragments thereof, antibodies of GRIR, and agonists, antagonists or inhibitors of GRIR, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Pharmaceutical compositions which

exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range  
5 depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may  
10 be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of  
15 the particular formulation.

Normal dosage amounts may vary from 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for  
20 nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## DIAGNOSTICS

In another embodiment, antibodies which specifically bind GRIR may be used for  
25 the diagnosis of disorders characterized by expression of GRIR, or in assays to monitor patients being treated with GRIR or agonists, antagonists, and inhibitors of GRIR. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for GRIR include methods which utilize the antibody and a label to detect GRIR in human body fluids or in extracts of cells  
30 or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent joining with a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GRIR, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GRIR expression. Normal or standard values for GRIR expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human,

5 with antibody to GRIR under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, preferably by photometric means. Quantities of GRIR expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

10 In another embodiment of the invention, the polynucleotides encoding GRIR may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of GRIR may be correlated with disease. The diagnostic assay may be

15 used to distinguish between absence, presence, and excess expression of GRIR, and to monitor regulation of GRIR levels during therapeutic intervention.

20 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GRIR or closely related molecules may be used to identify nucleic acid sequences which encode GRIR. The specificity of the probe, whether it is made from a highly specific region (e.g., the 5' regulatory region) or from a less specific region (e.g., the 3' coding region), and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding GRIR, alleles, or related sequences.

25 Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the GRIR encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequences of SEQ ID NO:2, SEQ ID NO:4, or from genomic sequences including promoter and enhancer elements and introns of the naturally

30 occurring GRIR.

Means for producing specific hybridization probes for DNAs encoding GRIR include the cloning of polynucleotide sequences encoding GRIR or GRIR derivatives into

vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by 5 radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GRIR may be used for the diagnosis of a disorder associated with expression of GRIR. Examples of a neoplastic disorder include, but are not limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, 10 sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. Examples of an immune response may be associated with, but are not limited to: AIDS, Addison's disease, adult respiratory distress 15 syndrome, allergies, anaphylaxis, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, cystic fibrosis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, chronic 20 granulomatous disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, rheumatoid arthritis, scleroderma, sickle cell anemia, Sjögren's syndrome, systemic sclerosis, thalassemia, ulcerative colitis, Werner syndrome, and complications of cancer, 25 hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. The polynucleotide sequences encoding GRIR may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patient biopsies to detect altered GRIR expression. Such qualitative 30 or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GRIR may be useful in assays that detect the presence of associated disorders, particularly those mentioned above.

The nucleotide sequences encoding GRIR may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the 5 patient sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding GRIR in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or 10 in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GRIR, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GRIR, under 15 conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard 20 values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of 25 treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health 30 professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences

encoding GRIR may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding GRIR, or a fragment of a polynucleotide complementary to the polynucleotide encoding GRIR, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of GRIR include radiolabeling or biotinyling nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244, and Duplaa, C. et al. (1993) Anal. Biochem. 229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image) and to identify genetic variants, mutations, and polymorphisms. This information may be used in determining gene function, in understanding the genetic basis of a disorder, in diagnosing a disorder, and in developing and monitoring the activities of therapeutic agents.

In one embodiment, the microarray is prepared and used according to methods known in the art, such as those described in published PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14:1675-1680), and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93:10614-10619).

The microarray is preferably composed of a large number of unique single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6 to 60 nucleotides in length, more preferably about 15 to 30 nucleotides in length, and most preferably about 20 to 25 nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are about 7 to 10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5' or 3' sequence, or may

contain sequential oligonucleotides which cover the full length sequence or unique oligonucleotides selected from particular areas along the length of the sequence.

Polynucleotides used in the microarray may be oligonucleotides specific to a gene or genes of interest in which at least a fragment of the sequence is known or oligonucleotides

5 specific to one or more unidentified cDNAs common to a particular cell or tissue type or to a normal, developmental, or disease state. In certain situations, it may be appropriate to use pairs of oligonucleotides on a microarray. The pairs will be identical, except for one nucleotide preferably located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs

10 may range from about 2 to 1,000,000.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' end, or, more preferably, at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In one aspect, the oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon, any other type of membrane, filter, chip, glass slide, or any other suitable solid support.

15 In one aspect, the oligonucleotides may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, such as that described in published PCT application WO95/251116 (Baldeschweiler et al.). In another aspect, a grid array analogous to a dot or slot blot (HYBRIDOT® apparatus, GIBCO/BRL) may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system or thermal, UV, mechanical or chemical bonding procedures. In yet another aspect, an array may be produced by hand or by using available devices, materials, and machines (including Brinkmann® multichannel pipettors or robotic instruments), and may contain 8, 24, 96, 384, 1536, or 6144 oligonucleotides, or 20 any other multiple from 2 to 1,000,000 which lends itself to the efficient use of commercially available instrumentation.

25 30 In order to conduct sample analysis using the microarrays, polynucleotides are extracted from a biological sample. The biological samples may be obtained from any bodily fluid (blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or

other tissue preparations. To produce probes, the polynucleotides extracted from the sample are used to produce nucleic acid sequences which are complementary to the nucleic acids on the microarray. If the microarray consists of cDNAs, antisense RNAs (aRNA) are appropriate probes. Therefore, in one aspect, mRNA is used to produce 5 cDNA which, in turn and in the presence of fluorescent nucleotides, is used to produce fragment or oligonucleotide aRNA probes. These fluorescently labeled probes are incubated with the microarray so that the probe sequences hybridize to the cDNA oligonucleotides of the microarray. In another aspect, nucleic acid sequences used as probes can include polynucleotides, fragments, and complementary or antisense sequences 10 produced using restriction enzymes, PCR technologies, and Oligolabeling or TransProbe kits (Pharmacia & Upjohn) well known in the area of hybridization technology.

Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal 15 of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine the degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies or for functional analysis of the sequences, 20 mutations, variants, or polymorphisms among samples. (Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155.)

In another embodiment of the invention, nucleic acid sequences encoding GRIR may be used to generate hybridization probes useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a 25 specific region of a chromosome, or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries, such as those reviewed in Price, C.M. (1993; Blood Rev. 7:127-134) and Trask, B.J. (1991; Trends Genet. 7:149-154).

Fluorescent in situ hybridization (FISH, as described, e.g., in Heinz-Ulrich, et al. 30 (1995) in Meyers, R.A. (ed.) Molecular Biology and Biotechnology, pp. 965-968, VCH Publishers New York, NY.) may be correlated with other physical chromosome mapping

techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding GRIR on a physical chromosomal map and a specific disorder, or predisposition to a specific disorder, may help define the 5 region of DNA associated with that disorder. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used 10 for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other 15 gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent 20 associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GRIR, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located 25 intracellularly. The formation of binding complexes between GRIR and the agent being tested may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564 (Geysen, et al.). In this 30 method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with GRIR, or fragments thereof, and washed. Bound GRIR is then detected by methods well

known in the art. Purified GRIR can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GRIR specifically compete with a test compound for binding GRIR. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GRIR.

In additional embodiments, the nucleotide sequences which encode GRIR may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

15

## EXAMPLES

### I. PROSNOT01 Cloning and Isolation of cDNAs

The prostate tissue used for library construction was obtained from a 78 year-old Caucasian male with leukemia (Lot No. 94-039, International Institute for the Advancement of Medicine, Exton PA). Patient history included skin cancer, emphysema, asthma, and a surgery for cholecystectomy. The patient was taking hydroxyurea for his leukemia.

The prostate tissue was flash frozen, ground in a mortar and pestle, lysed immediately in buffer containing guanidinium isothiocyanate and spun through cesium chloride. The lysate was extracted twice with phenol chloroform at pH 8.0 and centrifuged over a CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments). The RNA was precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in water and treated with DNase for 15 min at 37°C. The RNA was isolated using the Qiagen Oligotex kit (QIAGEN Inc., Chatsworth CA) and used to construct the cDNA library.

First strand cDNA synthesis was accomplished using an oligo d(T) primer/linker which also contained an XhoI restriction site. Second strand synthesis was performed

using a combination of DNA polymerase I, *E. coli* ligase and RNase H, followed by the addition of an EcoRI adaptor to the blunt ended cDNA. The EcoRI adapted, double-stranded cDNA was digested with Xhol restriction enzyme and fractionated on Sephadex S400 to obtain sequences which exceeded 1000 bp in size. The size selected cDNAs were 5 inserted into the LambdaZap® vector system (Stratagene, La Jolla CA); and the vector, which contains the pBluescript™ phagemid (Stratagene), was transformed into *E. coli*, strain XL1-BlueMRF™ (Stratagene).

The phagemid forms of individual cDNA clones were obtained by the *in vivo* excision process. Enzymes from both pBluescript and a cotransformed f1 helper phage 10 nicked the DNA, initiated new DNA synthesis, and created the smaller, single-stranded circular phagemid DNA molecules which contained the cDNA insert. The phagemid DNA was released, purified, and used to reinfect fresh host cells (SOLR, Stratagene). Presence of the phagemid which carries the gene for β-lactamase allowed transformed bacteria to grow on medium containing ampicillin.

15 Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit for Rapid Extraction Alkaline Lysis Plasmid Minipreps (Catalog #26173, QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific 20 Broth (Catalog #22711, GIBCO/BRL) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

25 Phagemid DNA was released from the cells and purified using the Miniprep Kit (Catalog # 77468; Advanced Genetic Technologies Corporation, Gaithersburg MD). This kit consists of a 96 well block with reagents for 960 purifications. The recommended protocol was employed except for the following changes: 1) the 96 wells were each filled with only 1 ml of sterile Terrific Broth (Catalog # 22711, GIBCO/BRL) with carbenicillin 30 at 25 mg/L and glycerol at 0.4%; 2) the bacteria were cultured for 24 hours after the wells were inoculated and then lysed with 60 µl of lysis buffer; 3) a centrifugation step employing the Beckman GS-6R @2900 rpm for 5 min was performed before the contents

of the block were added to the primary filter plate; and 4) the optional step of adding isopropanol to TRIS buffer was not routinely performed. After the last step in the protocol, samples were transferred to a Beckman 96-well block for storage.

Alternative methods of purifying plasmid DNA include the use of MAGIC 5 MINIPREP™ DNA purification system (Catalog #A7100, Promega, Madison WI) or QIAwell™-8 Plasmid, QIAwell PLUS DNA and QIAwell ULTRA DNA purification systems (QIAGEN).

## II. PROSTUT09 Cloning and Isolation of cDNAs

For the PROSTUT09 cDNA library, prostate tumor was obtained from a 66-year-old Caucasian male. Surgery included a radical prostatectomy, a radical cystectomy, and a urinary diversion to the intestine. The pathology report indicated an invasive grade 3 (of 3) transitional cell carcinoma located within the prostatic urethra which extended to involve periprostatic glands and diffusely invade the prostatic parenchyma anteriorly and posteriorly. All final surgical margins including ureters (left and right, after multiple re-excisions) and prostatic urethra were negative for tumor. In addition to extensive involvement by transitional cell carcinoma, the right prostate contained a microscopic focus of adenocarcinoma, Gleason grade 3+2, which was confined to the prostate and showed no capsular penetration. Multiple right and left pelvic lymph nodes were negative for tumor. The patient presented with prostatic inflammatory disease. The patient history included a previous transurethral prostatectomy, neoplasm of the lung, benign hypertension, and tobacco use. The patient was taking insulin and Dyazide® (diuretic/antihypertensive; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) at the time of surgery.

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysates were centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and treated with DNase at 37°C. RNA extraction and precipitation were repeated as before. The mRNA was isolated using the Qiagen Oligotex kit

(QIAGEN) and used to construct the cDNA libraries.

The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA synthesis and plasmid cloning (Catalog #18248-013, Gibco/BRL). The cDNAs were fractionated on a Sepharose CL4B column (Catalog #275105-01; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pINCY 1. The plasmid pINCY 1 was subsequently transformed into DH5a™ competent cells (Catalog #18258-012; Gibco/BRL)

### III. Sequencing and Homology Searching of cDNA Clones and Deduced Proteins

The cDNAs for PROSNOT01 and PROSTUT09 were sequenced by the method of Sanger F and AR Coulson (1975; J Mol Biol 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with four Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 or 373 DNA Sequencing Systems (Perkin Elmer). Reading frame was determined.

The nucleotide sequences and/or amino acid sequences of the Sequence Listing were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST (Basic Local Alignment Search Tool). (Altschul, S.F. (1993) J. Mol. Evol 36:290-300; and Altschul et al. (1990) J. Mol. Biol. 215:403-410.)

BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms such as the one described in Smith, T. et al. (1992; Protein Engineering 5:35-51), could have been used when dealing with primary sequence patterns and secondary structure gap penalties. The sequences disclosed in this application have lengths of at least 49 nucleotides and have no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In

this application, threshold was set at  $10^{-25}$  for nucleotides and  $10^{-10}$  for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam), and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp), for homology.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (Sambrook, supra, ch. 7 and Ausubel, F.M. et al. supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score, which is defined as:  $\frac{\text{identity} \times \% \text{ maximum BLAST score}}{100}$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding GRIR occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

## V. Extension of GRIR Encoding Polynucleotides

The nucleic acid sequences of Incyte Clones 364702 and 1650519 were used to design oligonucleotide primers for extending partial nucleotide sequences to full length. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (GIBCO/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
Step 3	68° C for 6 min
Step 4	94° C for 15 sec
Step 5	65° C for 1 min
Step 6	68° C for 7 min
Step 7	Repeat steps 4 through 6 for an additional 15 cycles
Step 8	94° C for 15 sec
Step 9	65° C for 1 min
Step 10	68° C for 7:15 min
Step 11	Repeat steps 8 through 10 for an additional 12 cycles
Step 12	72° C for 8 min
Step 13	4° C (and holding)

A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions

were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13  $\mu$ l of ligation buffer, 1 $\mu$ l T4-DNA ligase (15 units) and 1 $\mu$ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40  $\mu$ l of appropriate media) were transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium. (Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (Sambrook, *supra*, Appendix A, p. 1) containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150  $\mu$ l of liquid LB/2x Carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5  $\mu$ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5  $\mu$ l from each sample was transferred into a PCR array.

For PCR amplification, 18  $\mu$ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

20	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
25	Step 5	Repeat steps 2 through 4 for an additional 29 cycles
	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:2 or SEQ ID NO:4 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

## VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 or SEQ ID NO:4 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences) and labeled by combining 50 pmol of each oligomer and 250  $\mu$ Ci of [ $\gamma$ - $^{32}$ P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified using a Sephadex G-25 superfine resin column (Pharmacia & Upjohn). An aliquot containing  $10^7$  counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba 1, or Pvu II (DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

## VII. Microarrays

To produce oligonucleotides for a microarray, one of the nucleotide sequences of the present invention is examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that would interfere with hybridization. The algorithm identifies approximately 20 sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides are created in which one nucleotide in the center of each sequence is altered. This process is repeated for each gene in the microarray, and double sets of twenty 20-mers are synthesized and arranged on the surface

of the silicon chip using a light-directed chemical process, such as that described in Chee (supra.)

In the alternative, a chemical coupling procedure and an ink jet device are used to synthesize oligomers on the surface of a substrate. (Baldeschweiler, supra.) In another 5 alternative, a grid array analogous to a dot or slot blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system or thermal, UV, mechanical, or chemical bonding procedures. A typical array may be produced by hand or using available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots, or 6144 dots. After hybridization, the microarray is 10 washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of fluorescence. The scanned image is examined to determine the degree of complementarity and the relative abundance/expression level of each oligonucleotide sequence in the microarray.

15 **VIII. Complementary Polynucleotides**

Sequences complementary to the GRIR-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GRIR. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate 20 oligonucleotides are designed using Oligo 4.06 software and the coding sequence of GRIR. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GRIR-encoding transcript.

25

**IX. Expression of GRIR**

Expression of GRIR is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express GRIR in *E. coli*. This vector contains a promoter for  $\beta$ -galactosidase 30 upstream of the cloning site, followed by sequence containing the amino-terminal Met and the subsequent seven residues of  $\beta$ -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a

number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with isopropyl beta-D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein which consists of the first 8 residues of  $\beta$ -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of GRIR into bacterial growth media which can be used directly in the following assay for activity.

#### X. Demonstration of GRIR Activity

Receptors such as those encoded by SEQ ID NOs:2 and 4 may be expressed in heterologous expression systems and their biological activity tested utilizing the purinergic receptor system ( $P_{2U}$ ) as published by Erb, et al. (1993; Proc. Natl. Acad. Sci. 90:10449-53.) Because cultured K562 human leukemia cells lack  $P_{2U}$  receptors, they can be transfected with expression vectors containing either normal or chimeric  $P_{2U}$  and loaded with fura- $\alpha$ , fluorescent probe for  $Ca^{++}$ . Activation of properly assembled and functional extracellular SP-transmembrane/intracellular  $P_{2U}$  receptors with extracellular UTP or ATP mobilizes intracellular  $Ca^{++}$  which reacts with fura- $\alpha$  and is measured spectrofluorometrically. Bathing the transfected K562 cells in microwells containing appropriate ligands will trigger binding and fluorescent activity defining effectors of SP. Once ligand and function are established, the  $P_{2U}$  system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

#### XI. Production of GRIR Specific Antibodies

GRIR substantially purified using PAGE electrophoresis (Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The GRIR amino acid sequence is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel F.M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, ch. 11, John Wiley & Sons, New York, NY and by others.

Typically, the oligopeptides are 15 residues in length, and are synthesized using

an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to KLH (Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), following the procedure described in Ausubel et al., supra. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## XII. Purification of Naturally Occurring GRIR Using Specific Antibodies

Naturally occurring or recombinant GRIR is substantially purified by immunoaffinity chromatography using antibodies specific for GRIR. An immunoaffinity column is constructed by covalently coupling GRIR antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GRIR are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GRIR (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/ABBR binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GRIR is collected.

## XIII. Identification of Molecules Which Interact with GRIR

GRIR or biologically active fragments thereof are labeled with  $^{125}\text{I}$  Bolton-Hunter reagent. (Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GRIR, washed, and any wells with labeled GRIR complex are assayed. Data obtained using different concentrations of GRIR are used to calculate values for the number, affinity, and association of GRIR with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications

of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

What is claimed is:

1. A substantially purified G-protein coupled receptors associated with immune response (GRIR) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, and a fragment of SEQ ID NO:3.

5 2. A substantially purified variant of GRIR having at least 90% amino acid identity to the amino acid sequence of claim 1.

10 3. An isolated and purified polynucleotide sequence encoding the GRIR of claim 1.

15 4. An isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence of claim 3.

5. A composition comprising the polynucleotide sequence of claim 3.

20 6. An isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 3.

7. An isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3.

25 8. An isolated and purified polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:4.

30 9. A fragment of the polynucleotide sequence of claim 8, wherein the fragment is selected from the group consisting of:

- a) nucleotides 712 through nucleotide 783 of SEQ ID NO:2; and
- b) nucleotides 319 through 444 of SEQ ID NO:4.

10. An isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence of claim 8.

5 11. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.

12. A host cell containing the expression vector of claim 11.

10 13. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, a fragment of SEQ ID NO:1, or a fragment of SEQ ID NO:3, the method comprising the steps of:

- a) culturing the host cell of claim 12 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.

15

14. A pharmaceutical composition comprising the GRIR of claim 1 in conjunction with a suitable pharmaceutical carrier.

20 15. A purified antibody which specifically binds to the GRIR of claim 1.

16. A purified agonist of the GRIR of claim 1.

17. A purified antagonist of the GRIR of claim 1.

25 18. A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 17.

30 19. A method for treating or preventing an immune response, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 17.

20. A method for detecting a polynucleotide encoding GRIR in a biological sample containing nucleic acids, the method comprising the steps of:

(a) hybridizing the polynucleotide of claim 7 to at least one of the nucleic acids in the biological sample, thereby forming a hybridization complex; and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding GRIR in the biological sample.

10 21. The method of claim 19 wherein the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to hybridization.

1/15

9	18	27	36	45	54
GGC CAG GAC GGT GTC GAT CTC CTA ACC CCG TGA TCT GCC CTC CTC AGC CTC CCA					
63	72	81	90	99	108
GAG TGC TGG GAC TAC AGG CGT GAG CCA CCG CAT CTG GCC AAA CTT TCT GAT GAA					
117	126	135	144	153	162
AAC TCT AAG TCC ACC TAA GCT AAG GAC AGG AGT TAC AGC TTC CAT GAA TTT TAA					
171	180	189	198	207	216
AAC CAG ACC CAC CGA TTT GAG TAA GCA ATT ACT CTC TTG AAG GAG AAA AGT CAG					
225	234	243	252	261	270
AAA ACA TAA TGA TGA AAT CAC TAG GAC CTA ACT GGC ATG TGG AAT TAT TTT CTG					
279	288	297	306	315	324
CTT ATG AAC TAT CAA CTT TAA TTT CAT TTC CAG ATG ACA TGG TCT CAG CTG TTC					
333	342	351	360	369	378
TAC AGT GTT TAT AAA TGT TCT AAA TCA AGG GAA TTC ATC AAT CTA GTA GAA TAA					
387	396	405	414	423	432
AAT ATT TGA GTT CTT AAT TTC CTT TAA TTA GGA TAA CCT TTT TCT TCA AGT GAA					
441	450	459	468	477	486
GAG AAT GGT TTT ATT ACA TAG TTT TCT TCG GAA AAG ATA GGC TGT ATT TTC TAG					

FIGURE 1A

2/15

CAG	TTA	CGA	ATT	TGT	TAT	GTA	TGA	TGA	TCT	GGT	TCT	TGG	AAC	ATT	C <sup>r</sup> TT	GAA	TCT	540	
495	504	513	522	531	540														
AGT	GTC	TCT	AAG	GCA	GGT	GTG	TAC	AGC	AAG	AAG	TGA	ATA	ACA	CAG	AAA	TCA	ATG	549	
603	612	621	630	639	648														
ATG	AAA	GCA	TTA	GAA	GAC	AAT	TGA	GTC	TGT	CAG	AAC	TGC	AAA	ATA	TTG	CTG	AGT	603	
657	666	675	684	693	702														
GTG	GAT	TGC	TCT	GAA	ATC	TGA	AAA	CAT	TAC	TTG	TGA	ATT	GCT	TCT	ATT	CAA	ATT	657	
711	720	729	738	747	756														
GCA	GAC	ACA	ATG	CCA	GGT	GTR	TTA	CTR	GTR	TCC	CAT	TTT	TCA	ACC	CTC	GTR	M	711	
M	P	G	V	G	L	L	V	S	H	F	S	T	L	V					
765	774	783	792	801	810														
TCT	AGG	CAA	AGG	TGT	CCA	AAT	TAT	GCA	GAC	CCA	CAG	AAT	CTA	ACA	GAT	GTC	TCT	765	
S	R	C	P	N	Y	A	D	P	Q	N	L	T	D	V					
819	828	837	846	855	864														
ATA	TTC	CTC	CTC	CTA	GAA	GTC	TCA	GGG	GAT	CCA	GAA	CTG	CAG	CCA	GTC	CTT	GCT	I	819
I	F	L	L	E	V	S	G	D	P	E	L	Q	P	V	L	A			

FIGURE 1B

3/15

GGG	CTG	TTC	CTG	TCC	ATG	TGC	CTG	GTC	ACG	GTC	GGG	AAC	CTG	CTG	ATC	ATC	918
G	L	F	L	S	M	C	L	V	T	V	L	G	N	L	L	I	
873	882																909
927	936																909
CTG	CCC	ATC	AGC	CCT	GAC	TCC	CAC	CTC	CAC	ACC	CCC	ATG	TAC	TTC	CTC	TCC	972
L	A	I	S	P	D	S	H	L	H	T	P	M	Y	F	F	L	S
981	990																963
AAC	CTG	TCC	TTG	CCT	GAC	ATC	GGT	TTC	ACC	TCC	ACC	ACG	GTC	CCC	AAG	ATG	ATT
N	L	S	L	P	D	I	G	F	T	S	T	T	V	P	K	M	I
1035	1044																1017
GTG	GAC	ATC	CAG	TCT	CAC	AGC	AGA	GTC	ATC	TCC	TAT	GCA	GGC	TGC	ACT	CAG	1026
V	D	I	Q	S	H	S	R	V	I	S	Y	A	G	C	L	T	Q
1089	1098																1080
ATG	TCT	CTC	TTT	GCC	ATT	TTT	GGA	GGC	ATG	GAA	GAG	AGA	CAT	GCT	CCT	GAG	TGT
M	S	L	F	A	I	F	G	G	M	E	E	R	H	A	P	E	C
1143	1152																1134
GAT	GGC	CTA	TGA	CTG	GTT	TGT	AGC	CAT	CTG	TCA	CCC	GCT	ATA	TCA	TTC	ACC	ATC
D	G	L	*	L	V	C	S	H	L	S	P	A	I	S	F	T	I

FIGURE 1C

4 / 15

1197	1206	1215	1224	1233	1242
ATG AAC CCG TGT TTC TGT	GCC TTT CTA GTT TTG TTG	TCT TTT TTT CTC AGT			
M N P C F C A F L V	L S F F F L S				
1251	1260	1269	1278	1287	1296
CTT TTA GAC TCC CAG CTG CAC AAC TTG ATT GCC TTA CAA GTG ACC TGC TTC AAG					
L L D S Q L H N L I A L Q V T C F K					
1305	1314	1323	1332	1341	1350
GAT GTG GAA ATT CCT AAT TTC TTC TGT GAC CCT TCT CAA CTC TCC CAT CTT GCA					
D V E I P N F C D P S Q L S H L A					
1359	1368	1377	1386	1395	1404
TGT TGT GAC ACC TTC ACC ATT AAC ATA ATC ATG TAT TTC CCT GCT GCC ATA TTT					
C C D T F T I N I I M Y F P A A I F					
1413	1422	1431	1440	1449	1458
GGT TTT CTT CCC ATC TCA GGG ACC TTT TCT CTT ACT GTA AAA ATT CTT TCC TCC					
G F L P I S G T F S L T V K I L S S					
1467	1476	1485	1494	1503	1512
ATT CTG AGG GTT TCA TCA GGT GGG AAG TAT AAA CCT CCT CCT CCT GGT					
I L R V S S G G K Y K P S P P V G					

## FIGURE ID

5/15

1521	1530	1539	1548	1548	1557	1566
CTC ACC TGT CAG TTG TTT GCT GGA GGG TAC CTC GGT TCA GAT GTG TCA TCT TCC	L T C Q L F A G G Y L G S D V S S S					
1575	1584	1593	1602	1611	1620	1620
CCG AGA AAG AGT GCA GTG GCC TCA GTG ATG TAC ACG GTG GTC ACC CCC ATG CTG	P R K S A V A S V M Y T V V T P M L					
1629	1638	1647	1656	1665	1665	1674
AAC CCC TTC ATG TAC AGC CTG AGA AAC AGG GAT ATG AAA AGT GTC CTG CGG CGG	N P F M Y S L R N R D M K S V L R R					
1683	1692	1701	1710	1719	1728	
CCG CAC GGC AGC ACA GTC TAA TCT CAA TAT CTT ATT ATC TGT TCC ATT CCT TTT	P H G S T V					
1737	1746	1755	1764	1773	1782	
GTA GTG TGG GTT AAA AAA GGC AGC AAG ATC AAA TAA GAT TGA TCT CAG GAC CTG						
1791	1800	1809	1818	1827		
AAC ACT CAT GTT TGT ATA CGA CCG ACA AGT AGT CCC CGG AGG CCC G						

FIGURE 1E

6/15

1	M P G V G L L V S H F S T H V S R Q R C P N Y A D P O N I L T D V S I F I L L E V	364702
1	M - - - - -	- - - - -
1	M - - - - -	E L E N D T R I P E F I L L L G F
1	M - - - - -	D S S N B T R V S E F I L L L G F
1	M - - - - -	M G O N Q T S I S D F I L L L G L
41	S G D P E L O P V L A G L F L S M C L V T Y L G N L L I L I A I S P D S H L H T	364702
18	S E E P K L Q P F I F G L F L S M Y L V T I L G N L L I L A V S S D S H L H T	91314667
18	V E N K D L Q P L I Y G L F L S M Y L V T V I G N I S I I V A T I S D P C L H T	9205814
18	P I Q P E Q Q N L C Y A L F I A M Y I T T I L G N L L I I V L I R L D S H L H T	932086
81	P M Y F F L S N L S L P D I G F T S T T V P K M I V D I Q S H S R V I S Y A G C	364702
58	P M Y F F L A N L S F V D I C F T C T I P K M I V D I Q S H S R V I S Y A G C	91314667
58	P M Y F F L S N L S F V D I C F I S T T V P K M I V D I Q S H S R V I S Y A G C	9205814
58	P M Y F F L S N L S F S D L C E S S V T I P K L L Q N M Q N Q D P S I P Y A D C	932086
121	L T Q M S I F A I F G G M E E - - R H A P E C D G I L L - V C S H L S P A I S F T	364702
98	I I Q M Y F F E L F A G I D N F L L T V M A Y D R Y M A I C Y P I L H Y M V - - -	91314667
98	I T Q I Y F F L F V E L D N F L L T I M A Y D R Y V A I C H P M H Y T V - - -	9205814
98	L T O M Y F F L F G D I L E S F L L V A M A Y D R Y V A I C F P I L H Y T A - - -	932086
158	I M N P C F C A F L V L L S F F F L S S L L D S O L H N L I A L O V T C F K D V E	364702
135	I M N P Q L C S L L L V S W I - M S A L H S I L L Q T L M V L R L S F C T H F Q	91314667
135	I M N Y K L C G F L V L V S W I - V S V L H A L F Q S L M M L A L P F C T H L E	9205814
135	I M S P M L C L A L V A L S W V - L T T F H A M L H T L L M A R L C F C A D N V	932086
198	I P N F F C D P S O L S H L A C C D T F T I N I M Y F P A A I F G F I L P I S G	364702
174	I P H F F C C E L N O M I Q L A C C S D T F L N N M M L Y F A A I L L G V A P L V G	91314667
174	I P H Y F C C E P N O V I Q L T C S D A E L N D L V I Y F T L V L L A T V P P L A G	9205814
174	I P H F F C D M S A I L K L A F S D T R V N E W V I F I M G G L I L V I P F L L	932086

FIGURE 2A

7/15

**FIGURE 2B**

8/15

9	18	27	36	45	54
GGA GAA TTT GAA AGG GTG CCC CAA AGG ACA ATC TCT AAA GGG GTA AGG GGG ATA					
63	72	81	90	99	108
CCT ACC TTG TCT GGT AGG GGA GAT GTT TCG TTT TCA TGC TTT ACC AGA AAA TCC					
117	126	135	144	153	162
ACT TCC CTG CCG ACC TTA GTT TCA AAG CTT ATT CTT ATT TAG AGA CAA GAA ACC					
171	180	189	198	207	216
TGT TTC AAC TTG AAG ACA CCG TAT GAG GTG AAT GGA CAG CCA GCC ACC ACA ATG					
225	234	243	252	261	270
AAA GAA ATC AAA CCA GGA ATA ACC TAT GCT GAA CCC ACG CCT CAA TCG TCC CCA					
279	288	297	306	315	324
AGT GTT TCC TGA CAC GCA TCT TTG CTT ACA GTG CAT CAC AAC TGA AGA ATG GGG					
			M	G	
333	342	351	360	369	378
TTC AAC TTG ACG CTT GCA AAA TTA CCA AAT AAC GAG CTG CAC GGC CAA GAG AGT	F N L T L A K L P N N E L H G Q E S				
387	396	405	414	423	432
CAC AAT TCA GGC AAC AGG AGC GAC GGG CCA GGA AAG AAC ACC CTT CAC AAT	H N S G N R S D G P G K N T T L H N				

FIGURE 3A

9/15

GAA	TTT	GAC	ACA	ATT	GTC	TTG	CCG	GTG	CTT	TAT	CTC	ATT	ATA	TTT	GTG	GCA	AGC	
E	F	D	T	I	V	L	P	V	L	Y	L	I	I	F	V	A	S	
441	450																	486
																		477
495	504																	540
																		541
ATC	TTG	CTG	AAT	GGT	TTA	GCA	GTG	TGG	ATC	TTC	TTC	CAC	ATT	AGG	AAT	AAA	ACC	
I	L	N	G	L	A	V	W	I	F	F	H	I	R	N	K	T		
549	558																	594
																		595
AGC	TTC	ATA	TTC	TAT	CTC	AAA	AAC	ATA	GTG	GTG	GCA	GAC	CTC	ATA	ATG	ACG	CTG	
S	F	I	F	Y	L	K	N	I	V	V	A	D	L	I	M	T	L	
603	612																	648
																		649
ACA	TTT	CCA	TTT	CGA	ATA	GTC	CAT	GAT	GCA	GGG	TTT	GGA	CCT	TGG	TAC	TTC	AAG	
T	F	P	F	R	I	V	H	D	A	G	F	G	P	W	Y	F	K	
657	666																	702
																		756
TTT	ATT	CTC	TGC	AGA	TAC	ACT	TCA	GTT	TTG	TTT	TAT	GCA	AAC	ATG	TAT	ACT	TCC	
F	I	L	C	R	Y	T	S	V	L	F	Y	A	N	M	Y	T	S	
711	720																	756
																		756
ATC	GTG	TTC	CTT	GGG	CTG	ATA	AGC	ATT	GAT	CGC	TAT	CTG	AAG	GTG	GTC	AAG	CCA	
I	V	F	L	G	L	I	S	I	D	R	Y	L	K	V	V	K	P	

**FIGURE 3B**

10/15

	765	774	783	792	801	810
F	G	D	S	R	M	Y
TTC	GGG	GAC	TCT	CGG	ATG	TAC
A	C	T	C	G	A	G
AGC	ATC	ATA	ACC	TTC	ACG	AAG
TTT	GGG	TCT	CGG	ATG	TAC	AGC
819	828	837	846	855	864	
V	W	V	I	M	A	V
GTT	TGG	GTC	ATG	GCT	TTG	TCT
T	G	T	M	A	L	S
TTT	GTG	ATC	ATG	GCT	TTG	CCA
873	882	891	900	909	918	
Q	P	T	E	D	N	I
CAG	CCA	ACA	GAC	GAC	AAT	ATC
GTC	GGC	GCA	GCA	GTC	ACC	TAT
927	936	945	954	963	972	
V	K	W	H	T	A	V
TGC	AAA	TGG	CAT	ACG	GCA	GTC
981	990	999	1008	1017	1026	
L	V	I	L	I	G	C
CTG	CTG	ATC	GGT	TAC	ATA	GCC
1035	1044	1053	1062	1071	1080	
S	R	Q	F	I	S	Q
AGC	AGG	CAA	TTC	ATA	AGT	CAG
10NSDOCID: <WO 9929849A1>						

FIGURE 3C

11/15

1089	1098	1107	1116	1125	1134
AGG	GTT	GTC	TAT	TTT	ACC
R	V	V	A	V	F
M	P	S	T	F	S
1143	1152	1161	1170	1179	1188
ATG	CCT	TCT	ACT	TTT	AGT
M	P	S	T	F	H
1197	1206	1215	1224	1233	1242
ATC	CTA	TAT	TAC	TGC	AAA
I	L	Y	Y	C	K
1251	1260	1269	1278	1287	1296
CTG	GAT	CCA	ATA	ATT	TAC
L	D	P	I	I	Y
1305	1314	1323	1332	1341	1350
AAA	AAA	TCA	AAT	ATC	AGA
K	K	S	N	I	R
1359	1368	1377	1386	1395	1404
AGA	AGA	TCG	GAA	GTT	CGC
R	R	S	E	V	R
1413	1422	1431	1440		
TGT	TTC	TTC	GAA	TCG	ATA

FIGURE 3D

12/15

1	M G F N I L T L A K L P N N E L H G Q E S H N S G N R S D G P G K N T T L H N E F	1650519
1	M - - - - -	- - - - -
1	M E L N - - - - -	- - - - -
41	D T I V I L P V L Y L I I F V A S I L L N G L A V W I F - - -	F H I R N K T S F I 1650519
21	T Q Q I I P V L Y C M V F I A G I L L N G V S G W I F - - -	F Y V P S S K S F I q285995
14	R Y T L F P I V Y S T I I F V I L G I I T A N G Y V L W V F A R L Y P S K K L N E I K q49443	
78	F Y L K N I V V A D L I M T I L T F P F R I V H D A G F G P W Y F K F I I L C R Y T	1650519
58	I Y L K N I V V I A D F V M S I L T F P F K I L G D S G L G P W Q L N V F V C R V S	q285995
54	I F M V N L T V A D L F L I T T L P L W I V Y Y S N Q G N W F L P K F L C N L A	q49443
118	S V L F Y A N M Y T S I V F L G L I S I D R Y L K V V K P F G D S R M Y S I T E	1650519
98	A V L F Y V N M Y V S I V F E G L I S F D R Y Y K I T V K P L W T S F I Q S V S Y	q285995
94	G C L F F I N T Y C S V A F L G V I T Y N R F Q A V K Y P I K T A Q A T T R K R	q49443
158	T K V L S V C V W V I M A - - -	V L S L P N I I L T N G Q P T E D N I H D C 1650519
138	S K L L S V I V W M L M L - - -	L L A V P N I I L T N Q S V R E V T Q I K C q285995
134	G I A L S L V I V W V A I V A A A S Y F L V M D S T N V V S N K A G S G N I T R C	q49443

FIGURE 4A

13/15

193 SKLKSPLGVKWH~~TAVTYVN~~SCL - - - FVAVLVILLIGCYIAI 1650519  
 173 IELKSELGRKWH~~KASNYIFVAI~~I - - FWIVFLLIVFYTAI 9285995  
 174 FE-HYEKGSK - - - PVLIHICIVLGF~~FIVFLLILFCNLVI~~ 949443

230 SRYIHKS~~SRQFISQSSR~~-KRKHNO~~SIRVVAVYFTCFLLPY~~ 1650519  
 210 TKKIFKSHLKSSRN~~NTSVKKSSRNIF~~SIVFVFFVCFV~~VPHY~~ 9285995  
 210 IHTLLRQPVK-QQRNAEVRRRALWMVCTVLAV~~FVVICFVPH~~ 949443

269 HLCRMPSTF~~SHLDRLLDESAOKILYYCKEILTLFLSACNVC~~ 1650519  
 250 H~~IAARI~~PYTKSQ~~QTEAHYSCKEILRYMKEF~~TL~~LLSAANVC~~ 9285995  
 249 HMVQLPWT~~LAELG-MWPSSSNHQAINDAHQVTLCLLSTNCV~~ 949443

309 LDPIIYFFMCRSFSSRWLFKK~~SNIRPRSESIRSLQSVRSE~~ 1650519  
 290 LDPIIYFFL~~CQPFR~~EIL~~CKKLH~~IP~~PLKAQNNDLDIRIKRGN~~ 9285995  
 288 LD~~DFV~~YCELTK~~KER~~~~KHN~~SE~~KLNIM~~R~~SSQKCSRVTTDTGTE~~ 949443

349 VRIYYD~~YTD~~-~~V~~ 1650519  
 330 T~~TL~~-EST~~DL~~ 9285995  
 328 M~~A~~I~~PINH~~TPVN~~PINKN~~ 949443

FIGURE 4B

14 / 15

LIBRARY	CLONES	TISSUE DESCRIPTION
<b>Gastrointestinal</b>		
COLNNOT16	2	colon, sigmoid, 62 M, match to COLNTUT03
COLNTUT03	1	colon tumor, 62 M, match to COLNNOT16
EPIGNOT01	1	epiglottis
GBLANOT02	1	gallbladder, 21 M
PANCNOT15	1	pancreas, islet cell hyperplasia, 15 M
PANCNOT01	1	pancreas, 29 M
SINIUCT01	1	small intestine, ileum, 42 M
SININOT04	1	small intestine, ileum, Crohn's, 26 M
<b>Male reproductive</b>		
PROSNOT19	1	prostate, 59 M
PROSNOT01	1	prostate, 78 M
TESTNOT03	2	testis, 37 M
<b>Muscle</b>		
MUSCNOT07	1	muscle, forearm, 38 F
LVENNOT03	1	heart, left ventricle, 31 M
HEARNOT06	1	heart, 44 M
<b>Other</b>		
BLADTUT05	1	bladder tumor, 66 M, match to BLADNOT06
KIDNFET01	2	kidney, fetal, F
BRSTTUT01	1	breast tumor, 55 F, match to BRSTNOT02
BRSTNOT23	1	
KERANOT02	1	keratinocytes, primary cell line, 30 F
LUNGNOT03	1	lung tumor, 69 M, match to LUNGNOT15
BRAITUT13	1	brain tumor, meningioma, 68 M

FIGURE 5A

15/15

<u>LIBRARY</u>	<u>CLONES</u>	<u>TISSUE DESCRIPTION</u>
<b>Reproductive</b>		
PROSTUT09	2	prostate tumor, 66 M
PENITUT01	1	penis tumor, carcinoma, 64 M
PENGNOT01	1	penis, glans tissue removed along with neoplasm
OVARTU04	2	ovarian tumor, 53 F
<b>Other</b>		
NPOLNOT01	1	nasal polyp, 78 M
BLADNOT06	1	bladder, 66 M, match to BLADTUT05

FIGURE 5B

## SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

LAL, Preeti  
BANDMAN, Olga  
HILLMAN, Jennifer L.  
YUE, Henry

<120> G-PROTEIN COUPLED RECEPTORS ASSOCIATED WITH IMMUNE RESPONSE

<130> PF-0441 PCT

<140> To Be Assigned  
<141> Herewith

<150> 08/988,876

<151> 1997-12-11

<160> 9

<170> PERL PROGRAM

<210> 1

<211> 326

<212> PRT

<213> Homo sapiens

<220> -

<223> 364702

<400> 1

Met Pro Gly Val Gly Leu Leu Val Ser His Phe Ser Thr Leu Val  
1 5 10 15  
Ser Arg Gln Arg Cys Pro Asn Tyr Ala Asp Pro Gln Asn Leu Thr  
20 25 30  
Asp Val Ser Ile Phe Leu Leu Leu Glu Val Ser Gly Asp Pro Glu  
35 40 45  
Leu Gln Pro Val Leu Ala Gly Leu Phe Leu Ser Met Cys Leu Val  
50 55 60  
Thr Val Leu Gly Asn Leu Leu Ile Ile Leu Ala Ile Ser Pro Asp  
65 70 75  
Ser His Leu His Thr Pro Met Tyr Phe Phe Leu Ser Asn Leu Ser  
80 85 90  
Leu Pro Asp Ile Gly Phe Thr Ser Thr Thr Val Pro Lys Met Ile  
95 100 105  
Val Asp Ile Gln Ser His Ser Arg Val Ile Ser Tyr Ala Gly Cys  
110 115 120  
Leu Thr Gln Met Ser Leu Phe Ala Ile Phe Gly Gly Met Glu Glu  
125 130 135  
Arg His Ala Pro Glu Cys Asp Gly Leu Leu Val Cys Ser His Leu  
140 145 150  
Ser Pro Ala Ile Ser Phe Thr Ile Met Asn Pro Cys Phe Cys Ala  
155 160 165  
Phe Leu Val Leu Leu Ser Phe Phe Phe Leu Ser Leu Leu Asp Ser  
170 175 180  
Gln Leu His Asn Leu Ile Ala Leu Gln Val Thr Cys Phe Lys Asp  
185 190 195  
Val Glu Ile Pro Asn Phe Phe Cys Asp Pro Ser Gln Leu Ser His  
200 205 210  
Leu Ala Cys Cys Asp Thr Phe Thr Ile Asn Ile Ile Met Tyr Phe

215	220	225
Pro Ala Ala Ile Phe Gly Phe Leu Pro Ile Ser Gly Thr Phe Ser		
230	235	240
Leu Thr Val Lys Ile Leu Ser Ser Ile Leu Arg Val Ser Ser Ser		
245	250	255
Gly Gly Lys Tyr Lys Pro Ser Pro Pro Val Gly Leu Thr Cys Gln		
260	265	270
Leu Phe Ala Gly Gly Tyr Leu Gly Ser Asp Val Ser Ser Ser Pro		
275	280	285
Arg Lys Ser Ala Val Ala Ser Val Met Tyr Thr Val Val Thr Pro		
290	295	300
Met Leu Asn Pro Phe Met Tyr Ser Leu Arg Asn Arg Asp Met Lys		
305	310	315
Ser Val Leu Arg Arg Pro His Gly Ser Thr Val		
320	325	

<210> 2  
<211> 1828  
<212> DNA  
<213> Homo sapiens

<220> -  
<223> 364702

<400> 2

```

ggccaggacg gtgtcgatct cctaaccggc tgatctgccc tcctcagcct cccagagtgc 60
tggactaca ggcgtgagcc accgcacatcg gccaaacttt ctgatgaaaa ctctaagtcc 120
acctaagcta aggacaggag ttacagcttc catgaatttt aaaaccagac ccaccgattt 180
gagtaagcaa ttactcttctt gaaggagaaa agtcagaaaa cataatgatg aaatcactag 240
gacctaactg gcatgtggaa ttatttctg ctatgaact atcaacttta atttcatttc 300
cagatgacat ggtctcagct gttctacagt gtttataaat gttctaaatc aaggaaatc 360
atcaatctag tagaataaaa tatttgaggctt ctaatttcc ttaatttagg ataacctttt 420
tcttcaagtg aagagaatgg ttttattaca tagtttctt cgaaaaagat aggctgtatt 480
ttcttagcaatc tagcaatttg ttatgtatga tgatctgggtt cttgaaacat tcttgaatct 540
agtgtctcta aggcaagggtt gtacagcaag aagtgaataa cacagaaatc aatgtgaaa 600
gcatttagaag acaatttgagt ctgtcagaac tgcaaaaatat tgctgagtgt ggattgctct 660
gaaatctgaa aacattactt gtgaatttgct tctattcaaa atgcagacac aatgccaggt 720
gttggtttac ttgttccca ttttcaacc ctcgttctta ggcaaaagggtg tccaaattat 780
gcagaccac agaatctaacc agatgtctct atattcctcc tcctagaagt ctcagggat 840
ccagaactgc agccagtcct tgctggctg ttctctgtcca tgcctgggt cacgggtctg 900
gggaacctgc tcatcatcct ggcacatcgc cctgactccc acctccacac ccccatgtac 960
ttcttcctct ccaacacctgc ctgcctgac atcggttca cctccaccac ggtccccaaag 1020
atgattgtgg acatccagtc tcacagcaga gtcatctcct atgcaggctg cctgactcag 1080
atgtctctt ttgcctttt tggaggcatg gaagagagac atgctcttgc gtgtgatggc 1140
ctatgactgg ttttagccat tctgtcaccc getatatcat tcaccatcat gaaccggtgt 1200
ttctgtgcct ttcttagttt gttgtctttt tttttctca gtcttttaga ctcccaagctg 1260
cacaacttga ttgccttaca agtgacatgc ttcaggatgc tggaaattcc taatttcttc 1320
tgtgaccctt ctcaactctc ccatcttgc tttgtgaca ctttccatcat taacataatc 1380
atgtatccc ctgcgtccat atttgggtt cttccatcat cagggacctt ttcttctact 1440
gtaaaaattc tttccatcat tctgagggtt tcacatcatcg gtggaaagta taaaccttt 1500
ccacccgtgg gtctcacctg tcagttgtt gctggagggtt accttcggttc agatgtgtca 1560
tttccccca gaaagagtgc agtggcctca gtgtatgtaca cggtggtcac ccccatgtcg 1620
aacccttca tgtacagcct gagaaacagg gatatgaaaa gtgtcctgcg gccggccgac 1680
ggcagcacag tctaattctca atatcttctt atctgttcca ttcctttgtt agtgtgggtt 1740
aaaaaaggca gcaagatcaa ataagattga tctcaggacc tgaacactca tgggggtata 1800
cgaccgacaa gtagtcccccg gaggcccg 1828

```

<210> 3  
<211> 358  
<212> PRT

&lt;213&gt; Homo sapiens

<220> -  
<223> 1650519

&lt;400&gt; 3

Met	Gly	Phe	Asn	Leu	Thr	Leu	Ala	Lys	Leu	Pro	Asn	Asn	Glu	Leu
1				5				10					15	
His	Gly	Gln	Glu	Ser	His	Asn	Ser	Gly	Asn	Arg	Ser	Asp	Gly	Pro
				20				25					30	
Gly	Lys	Asn	Thr	Thr	Leu	His	Asn	Glu	Phe	Asp	Thr	Ile	Val	Leu
				35				40					45	
Pro	Val	Leu	Tyr	Leu	Ile	Ile	Phe	Val	Ala	Ser	Ile	Leu	Leu	Asn
				50				55					60	
Gly	Leu	Ala	Val	Trp	Ile	Phe	Phe	His	Ile	Arg	Asn	Lys	Thr	Ser
				65				70					75	
Phe	Ile	Phe	Tyr	Leu	Lys	Asn	Ile	Val	Val	Ala	Asp	Leu	Ile	Met
				80				85					90	
Thr	Leu	Thr	Phe	Pro	Phe	Arg	Ile	Val	His	Asp	Ala	Gly	Phe	Gly
				95				100					105	
Pro	Trp	Tyr	Phe	Lys	Phe	Ile	Leu	Cys	Arg	Tyr	Thr	Ser	Val	Leu
				110				115					120	
Phe	Tyr	Ala	Asn	Met	Tyr	Thr	Ser	Ile	Val	Phe	Leu	Gly	Leu	Ile
				125				130					135	
Ser	Ile	Asp	Arg	Tyr	Leu	Lys	Val	Val	Lys	Pro	Phe	Gly	Asp	Ser
				140				145					150	
Arg	Met	Tyr	Ser	Ile	Thr	Phe	Thr	Lys	Val	Leu	Ser	Val	Cys	Val
				155				160					165	
Trp	Val	Ile	Met	Ala	Val	Leu	Ser	Leu	Pro	Asn	Ile	Ile	Leu	Thr
				170				175					180	
Asn	Gly	Gln	Pro	Thr	Glu	Asp	Asn	Ile	His	Asp	Cys	Ser	Lys	Leu
				185				190					195	
Lys	Ser	Pro	Leu	Gly	Val	Lys	Trp	His	Thr	Ala	Val	Thr	Tyr	Val
				200				205					210	
Asn	Ser	Cys	Leu	Phe	Val	Ala	Val	Leu	Val	Ile	Leu	Ile	Gly	Cys
				215				220					225	
Tyr	Ile	Ala	Ile	Ser	Arg	Tyr	Ile	His	Lys	Ser	Ser	Arg	Gln	Phe
				230				235					240	
Ile	Ser	Gln	Ser	Ser	Arg	Lys	Arg	Lys	His	Asn	Gln	Ser	Ile	Arg
				245				250					255	
Val	Val	Val	Ala	Val	Tyr	Phe	Thr	Cys	Phe	Leu	Pro	Tyr	His	Leu
				260				265					270	
Cys	Arg	Met	Pro	Ser	Thr	Phe	Ser	His	Leu	Asp	Arg	Leu	Leu	Asp
				275				280					285	
Glu	Ser	Ala	Gln	Lys	Ile	Leu	Tyr	Tyr	Cys	Lys	Glu	Ile	Thr	Leu
				290				295					300	
Phe	Leu	Ser	Ala	Cys	Asn	Val	Cys	Leu	Asp	Pro	Ile	Ile	Tyr	Phe
				305				310					315	
Phe	Met	Cys	Arg	Ser	Phe	Ser	Arg	Trp	Leu	Phe	Lys	Lys	Ser	Asn
				320				325					330	
Ile	Arg	Pro	Arg	Ser	Glu	Ser	Ile	Arg	Ser	Leu	Gln	Ser	Val	Arg
				335				340					345	
Arg	Ser	Glu	Val	Arg	Ile	Tyr	Tyr	Asp	Tyr	Thr	Asp	Val		
				350				355						

<210> 4  
<211> 1444  
<212> DNA  
<213> Homo sapiens

<220> -  
 <223> 1650519

<400> 4  
 ggagaatttg aaagggtgcc ccaaaggaca atctctaaag gggtaagggg gatacctacc 60  
 ttgtctggta ggggagatgt ttcgtttca tgcttacca gaaaatccac ttccctgccc 120  
 accttagtt caaagcttat tcttaattag agacaagaaa cctgttcaa cttgaagaca 180  
 ccgtatgagg tgaatggaca gccagccacc acaatgaaag aatcaaacc agaataacc 240  
 tatgctgaac ccacgcctca atcgccccca agtgtttcct gacacgcac tttgcttaca 300

gtgcatcaca actgaagaat ggggttcaac ttgacgcttg caaaattacc aaataaacgag 360  
 ctgcacggcc aagagagtca caattcaggc aacaggagcg acggggccagg aaagaacacc 420  
 acccttcaca atgaatttga cacaattgtc ttgcccgtgc tttatctcat tatatttg 480  
 gcaagcatct tgctgaatgg tttagcagtg tggatcttct tccacattag gaataaaacc 540  
 agcttcatat tctatctcaa aaacatagtg gttgcagacc tcataatgac gctgacatt 600  
 ccatttcgaa tagtccatga tgcaggattt ggaccttggg acttcaagtt tattctctgc 660  
 agatacacctt cagttttgtt ttatgcaaac atgtataactt ccatctgttt ccttgggctg 720  
 ataaggatcg atcgctatct gaaggtggc aagccattt gggactctcg gatgtacagc 780  
 ataaccttca cgaaggttt atctgtttgtt gttgggtga tcatggctgt tttgtctttg 840  
 ccaaacatca tcctgacaaa tggtcagcca acagaggaca atatccatga ctgctaaaaa 900  
 cttaaaaatgc ctgggggggt caaatggcat acggcagtca cctatgtgaa cagctgcttg 960  
 ttgtggccg tgctgtgtat tctgtatcgga ttttacatcgatccatccac 1020  
 aaatccagca ggcaattcat aagtctgtca agccgaaagc gaaaacataa ccagagcatc 1080  
 agggttggtggc tggctgtat ttttacatcgatccatccatccac 1140  
 tctacttttta gtcactttaga caggcttttta gatgaatctg cacaaaaaat cctatattac 1200  
 tgcaaaagaaa ttacactttt cttgtctcg tggatgttt gcctggatcc aataatttac 1260  
 ttttcatgtt gttaggtcatt ttcaagatgg ctgttcaaaa aatcaaataat cagacccagg 1320  
 agtggaaagca tcagatcact gcaaaatgtg agaagatcgg aagttcgcat attatattat 1380  
 tacactgatg tggatggcattt ttattgtttt gttggatcga tatgtacaaa gtgtatataca 1440  
 tcag 1444

<210> 5  
 <211> 309  
 <212> PRT  
 <213> Canis familiaris

<220> -  
 <223> g1314667

<400> 5  
 Met Glu Leu Glu Asn Asp Thr Arg Ile Pro Glu Phe Leu Leu Leu  
 1 5 10 15  
 Gly Phe Ser Glu Glu Pro Lys Leu Gln Pro Phe Leu Phe Gly Leu  
 20 25 30  
 Phe Leu Ser Met Tyr Leu Val Thr Ile Leu Gly Asn Leu Leu Leu  
 35 40 45  
 Ile Leu Ala Val Ser Ser Asp Ser His Leu His Thr Pro Met Tyr  
 50 55 60  
 Phe Phe Leu Ala Asn Leu Ser Phe Val Asp Ile Cys Phe Thr Cys  
 65 70 75  
 Thr Thr Ile Pro Lys Met Leu Val Asn Ile Gln Thr Gln Arg Lys  
 80 85 90  
 Val Ile Thr Tyr Glu Ser Cys Ile Ile Gln Met Tyr Phe Phe Glu  
 95 100 105  
 Leu Phe Ala Gly Ile Asp Asn Phe Leu Leu Thr Val Met Ala Tyr  
 110 115 120  
 Asp Arg Tyr Met Ala Ile Cys Tyr Pro Leu His Tyr Met Val Ile  
 125 130 135  
 Met Asn Pro Gln Leu Cys Ser Leu Leu Leu Leu Val Ser Trp Ile  
 140 145 150  
 Met Ser Ala Leu His Ser Leu Leu Gln Thr Leu Met Val Leu Arg  
 155 160 165

Leu	Ser	Phe	Cys	Thr	His	Phe	Gln	Ile	Pro	His	Phe	Phe	Cys	Glu
				170				175						180
Leu	Asn	Gln	Met	Ile	Gln	Leu	Ala	Cys	Ser	Asp	Thr	Phe	Ieu	Asn
				185				190						195
Asn	Met	Met	Leu	Tyr	Phe	Ala	Ala	Ile	Leu	Leu	Gly	Val	Ala	Prc
				200				205						210
Leu	Val	Gly	Val	Leu	Tyr	Ser	Tyr	Phe	Lys	Ile	Val	Ser	Ser	Ile
				215				220						225
Arg	Gly	Ile	Ser	Ser	Ala	His	Ser	Lys	Tyr	Lys	Ala	Phe	Ser	Thr
				230				235						240
Cys	Ala	Ser	His	Leu	Ser	Val	Val	Ser	Leu	Phe	Tyr	Cys	Thr	Ser
				245				250						255

Leu	Gly	Val	Tyr	Leu	Ser	Ser	Ala	Ala	Pro	Gln	Ser	Thr	His	Thr
				260				265						270
Ser	Ser	Val	Ala	Ser	Val	Met	Tyr	Thr	Val	Val	Thr	Pro	Met	Leu
				275				280						285
Asn	Pro	Phe	Ile	Tyr	Ser	Leu	Arg	Asn	Lys	Asp	Ile	Lys	Gly	Ala
				290				295						300
Leu	Asn	Val	Phe	Phe	Arg	Gly	Lys	Pro						
				305										

<210> 6  
<211> 333  
<212> PRT  
<213> Rattus norvegicus

<220> -  
<223> g205814

<400> 6														
Met	Asp	Ser	Ser	Asn	Arg	Thr	Arg	Val	Ser	Glu	Phe	Leu	Leu	Leu
1				5				10						15
Gly	Phe	Val	Glu	Asn	Lys	Asp	Leu	Gln	Pro	Leu	Ile	Tyr	Gly	Leu
				20				25						30
Phe	Leu	Ser	Met	Tyr	Leu	Val	Thr	Val	Ile	Gly	Asn	Ile	Ser	Ile
				35				40						45
Ile	Val	Ala	Ile	Ile	Ser	Asp	Pro	Cys	Leu	His	Thr	Pro	Met	Tyr
				50				55						60
Phe	Phe	Leu	Ser	Asn	Leu	Ser	Phe	Val	Asp	Ile	Cys	Phe	Ile	Ser
				65				70						75
Thr	Thr	Val	Pro	Lys	Met	Leu	Val	Asn	Ile	Gln	Thr	Gln	Asn	Asn
				80				85						90
Val	Ile	Thr	Tyr	Ala	Gly	Cys	Ile	Thr	Gln	Ile	Tyr	Phe	Phe	Leu
				95				100						105
Leu	Phe	Val	Glu	Leu	Asp	Asn	Phe	Leu	Leu	Thr	Ile	Met	Ala	Tyr
				110				115						120
Asp	Arg	Tyr	Val	Ala	Ile	Cys	His	Pro	Met	His	Tyr	Thr	Val	Ile
				125				130						135
Met	Asn	Tyr	Lys	Leu	Cys	Gly	Phe	Leu	Val	Leu	Val	Ser	Trp	Ile
				140				145						150
Val	Ser	Val	Leu	His	Ala	Leu	Phe	Gln	Ser	Leu	Met	Met	Leu	Ala
				155				160						165
Leu	Pro	Phe	Cys	Thr	His	Leu	Glu	Ile	Pro	His	Tyr	Phe	Cys	Glu
				170				175						180
Pro	Asn	Gln	Val	Ile	Gln	Leu	Thr	Cys	Ser	Asp	Ala	Phe	Leu	Asn
				185				190						195
Asp	Leu	Val	Ile	Tyr	Phe	Thr	Leu	Val	Leu	Leu	Ala	Thr	Val	Pro
				200				205						210
Leu	Ala	Gly	Ile	Phe	Tyr	Ser	Tyr	Phe	Lys	Ile	Val	Ser	Ser	Ile
				215				220						225
Cys	Ala	Ile	Ser	Ser	Val	His	Gly	Lys	Tyr	Lys	Ala	Phe	Ser	Thr

230	235	240
Cys Ala Ser His Leu Ser Val Val Ser Leu Phe Tyr Cys Thr Gly		
245	250	255
Leu Gly Val Tyr Leu Ser Ser Ala Ala Asn Asn Ser Ser Gln Ala		
260	265	270
Ser Ala Thr Ala Ser Val Met Tyr Thr Val Val Thr Pro Met Val		
275	280	285
Asn Pro Phe Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Ser Val		
290	295	300
Leu Lys Lys Thr Leu Cys Glu Glu Val Ile Arg Ser Pro Pro Ser		
305	310	315
Leu Leu His Phe Phe Leu Val Leu Cys His Leu Pro Cys Phe Ile		
320	325	330
Phe Cys Tyr		

<210> 7  
<211> 314  
<212> PRT  
<213> Homo sapiens

<220> -  
<223> g32086

<400> 7		
Met Met Gly Gln Asn Gln Thr Ser Ile Ser Asp Phe Leu Leu Leu		
1 5 10 15		
Gly Leu Pro Ile Gln Pro Glu Gln Gln Asn Leu Cys Tyr Ala Leu		
20 25 30		
Phe Leu Ala Met Tyr Leu Thr Thr Leu Leu Gly Asn Leu Leu Ile		
35 40 45		
Ile Val Leu Ile Arg Leu Asp Ser His Leu His Thr Pro Met Tyr		
50 55 60		
Leu Phe Leu Ser Asn Leu Ser Phe Ser Asp Leu Cys Phe Ser Ser		
65 70 75		
Val Thr Ile Pro Lys Leu Leu Gln Asn Met Gln Asn Gln Asp Pro		
80 85 90		
Ser Ile Pro Tyr Ala Asp Cys Leu Thr Gln Met Tyr Phe Phe Leu		
95 100 105		
Leu Phe Gly Asp Leu Glu Ser Phe Leu Leu Val Ala Met Ala Tyr		
110 115 120		
Asp Arg Tyr Val Ala Ile Cys Phe Pro Leu His Tyr Thr Ala Ile		
125 130 135		
Met Ser Pro Met Leu Cys Leu Ala Leu Val Ala Leu Ser Trp Val		
140 145 150		
Leu Thr Thr Phe His Ala Met Leu His Thr Leu Leu Met Ala Arg		
155 160 165		
Leu Cys Phe Cys Ala Asp Asn Val Ile Pro His Phe Phe Cys Asp		
170 175 180		
Met Ser Ala Leu Leu Lys Leu Ala Phe Ser Asp Thr Arg Val Asn		
185 190 195		
Glu Trp Val Ile Phe Ile Met Gly Gly Leu Ile Leu Val Ile Pro		
200 205 210		
Phe Leu Leu Ile Leu Gly Ser Tyr Ala Arg Ile Val Ser Ser Ile		
215 220 225		
Leu Lys Val Pro Ser Ser Lys Gly Ile Cys Lys Ala Phe Ser Thr		
230 235 240		
Cys Gly Ser His Leu Ser Val Val Ser Leu Phe Tyr Gly Thr Val		
245 250 255		
Ile Gly Leu Tyr Leu Cys Ser Ser Ala Asn Ser Ser Thr Leu Lys		
260 265 270		
Asp Thr Val Met Ala Met Met Tyr Thr Val Val Thr Pro Met Leu		
275 280 285		

Asn	Pro	Phe	Ile	Tyr	Ser	Leu	Arg	Asn	Arg	Asp	Met	Lys	Gly	Ala
				290				295						300
Leu	Ser	Arg	Val	Ile	His	Gln	Lys	Lys	Thr	Phe	Phe	Ser	Leu	
				305				310						

<210> 8  
<211> 338  
<212> PRT  
<213> Homo sapiens

<220> -  
<223> g285995

<400> 8  
Met Ile Asn Ser Thr Ser Thr Gln Pro Pro Asp Glu Ser Cys Ser  
1 5 10 15  
Gln Asn Leu Leu Ile Thr Gln Gln Ile Ile Pro Val Leu Tyr Cys

20	25	30												
Met	Val	Phe	Ile	Ala	Gly	Ile	Leu	Leu	Asn	Gly	Val	Ser	Gly	Trp
					35				40					45
Ile	Phe	Phe	Tyr	Val	Pro	Ser	Ser	Lys	Ser	Phe	Ile	Ile	Tyr	Leu
					50				55					60
Lys	Asn	Ile	Val	Ile	Ala	Asp	Phe	Val	Met	Ser	Leu	Thr	Phe	Pro
					65				70					75
Phe	Lys	Ile	Leu	Gly	Asp	Ser	Gly	Leu	Gly	Pro	Trp	Gln	Leu	Asn
					80				85					90
Val	Phe	Val	Cys	Arg	Val	Ser	Ala	Val	Leu	Phe	Tyr	Val	Asn	Met
					95				100					105
Tyr	Val	Ser	Ile	Val	Phe	Phe	Gly	Leu	Ile	Ser	Phe	Asp	Arg	Tyr
					110				115					120
Tyr	Lys	Ile	Val	Lys	Pro	Leu	Trp	Thr	Ser	Phe	Ile	Gln	Ser	Val
					125				130					135
Ser	Tyr	Ser	Lys	Leu	Leu	Ser	Val	Ile	Val	Trp	Met	Leu	Met	Leu
					140				145					150
Leu	Leu	Ala	Val	Pro	Asn	Ile	Ile	Leu	Thr	Asn	Gln	Ser	Val	Arg
					155				160					165
Glu	Val	Thr	Gln	Ile	Lys	Cys	Ile	Glu	Leu	Lys	Ser	Glu	Leu	Gly
					170				175					180
Arg	Lys	Trp	His	Lys	Ala	Ser	Asn	Tyr	Ile	Phe	Val	Ala	Ile	Phe
					185				190					195
Trp	Ile	Val	Phe	Leu	Leu	Leu	Ile	Val	Phe	Tyr	Thr	Ala	Ile	Thr
					200				205					210
Lys	Lys	Ile	Phe	Lys	Ser	His	Leu	Lys	Ser	Ser	Arg	Asn	Ser	Thr
					215				220					225
Ser	Val	Lys	Lys	Lys	Ser	Ser	Arg	Asn	Ile	Phe	Ser	Ile	Val	Phe
					230				235					240
Val	Phe	Phe	Val	Cys	Phe	Val	Pro	Tyr	His	Ile	Ala	Arg	Ile	Pro
					245				250					255
Tyr	Thr	Lys	Ser	Gln	Thr	Glu	Ala	His	Tyr	Ser	Cys	Gln	Ser	Lys
					260				265					270
Glu	Ile	Leu	Arg	Tyr	Met	Lys	Glu	Phe	Thr	Leu	Leu	Leu	Ser	Ala
					275				280					285
Ala	Asn	Val	Cys	Leu	Asp	Pro	Ile	Ile	Tyr	Phe	Phe	Leu	Cys	Gln
					290				295					300
Pro	Phe	Arg	Glu	Ile	Leu	Cys	Lys	Lys	Leu	His	Ile	Pro	Leu	Lys
					305				310					315
Ala	Gln	Asn	Asp	Leu	Asp	Ile	Ser	Arg	Ile	Lys	Arg	Gly	Asn	Thr
					320				325					330
Thr	Leu	Glu	Ser	Thr	Asp	Thr	Leu							
					335									

<210> 9  
<211> 342  
<212> PRT  
<213> Cavia cutleri

<220> -  
<223> g49443

<400> 9  
Met Glu Leu Asn Ser Ser Ser Arg Val Asp Ser Glu Phe Arg Tyr  
1 5 10 15  
Thr Leu Phe Pro Ile Val Tyr Ser Ile Ile Phe Val Leu Gly Ile  
20 25 30  
Ile Ala Asn Gly Tyr Val Leu Trp Val Phe Ala Arg Leu Tyr Pro  
35 40 45  
Ser Lys Lys Leu Asn Glu Ile Lys Ile Phe Met Val Asn Leu Thr  
50 55 60  
Val Ala Asp Leu Leu Phe Leu Ile Thr Leu Pro Leu Trp Ile Val  
65 70 75  
Tyr Tyr Ser Asn Gln Gly Asn Trp Phe Leu Pro Lys Phe Leu Cys  
80 85 90  
Asn Leu Ala Gly Cys Leu Phe Phe Ile Asn Thr Tyr Cys Ser Val  
95 100 105  
Ala Phe Leu Gly Val Ile Thr Tyr Asn Arg Phe Gln Ala Val Lys  
110 115 120  
Tyr Pro Ile Lys Thr Ala Gln Ala Thr Thr Arg Lys Arg Gly Ile  
125 130 135  
Ala Leu Ser Leu Val Ile Trp Val Ala Ile Val Ala Ala Ala Ser  
140 145 150  
Tyr Phe Leu Val Met Asp Ser Thr Asn Val Val Ser Asn Lys Ala  
155 160 165  
Gly Ser Gly Asn Ile Thr Arg Cys Phe Glu His Tyr Glu Lys Gly  
170 175 180  
Ser Lys Pro Val Leu Ile Ile His Ile Cys Ile Val Leu Gly Phe  
185 190 195  
Phe Ile Val Phe Leu Leu Ile Leu Phe Cys Asn Leu Val Ile Ile  
200 205 210  
His Thr Leu Leu Arg Gln Pro Val Lys Gln Gln Arg Asn Ala Glu  
215 220 225  
Val Arg Arg Arg Ala Leu Trp Met Val Cys Thr Val Leu Ala Val  
230 235 240  
Phe Val Ile Cys Phe Val Pro His His Met Val Gln Leu Pro Trp  
245 250 255  
Thr Leu Ala Glu Leu Gly Met Trp Pro Ser Ser Asn His Gln Ala  
260 265 270  
Ile Asn Asp Ala His Gln Val Thr Leu Cys Leu Leu Ser Thr Asn  
275 280 285  
Cys Val Leu Asp Pro Val Ile Tyr Cys Phe Leu Thr Lys Lys Phe  
290 295 300  
Arg Lys His Leu Ser Glu Lys Leu Asn Ile Met Arg Ser Ser Gln  
305 310 315  
Lys Cys Ser Arg Val Thr Thr Asp Thr Gly Thr Glu Met Ala Ile  
320 325 330  
Pro Ile Asn His Thr Pro Val Asn Pro Ile Lys Asn  
335 340

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/25565

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 A61K38/16 G01N33/68 C12Q1/68  
C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C07K A61K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL, ID HSA42813 Accession number AA042813 7 September 1996 99% identity with Seq.ID:2 nt.709-1208 reverse orientation XP002100507 see the whole document ---	1-13, 15, 20, 21
Y		14, 16-19
X	Database EMBL, ID AA626037 Accession number AA626037 28 October 1997 99% identity with Seq.ID:2 nt.908-1352 reverse orientation XP002100508 see the whole document ---	1-8, 10-13, 15, 20, 21
Y		14, 16-19
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 April 1999

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/25565

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 39511 A (INCYTE PHARMACEUTICALS INC (US); COLEMAN; AU-YOUNG; BANDMAN; SEILHAMER) 12 December 1996 see abstract see page 29 - page 30; claims ----	14,16-19
X	Database EMBL, ID HS920360 Accession number W79920 27 June 1996 98% identity with Seq.ID:4 nt.1025-1436 reverse orientation XP002100509	1-8, 10-13, 15,20,21
Y	see the whole document ----	14,16-19
X	Database EMBL, ID HS123364 Accession number W79123 27 June 1996 98% identity with Seq.ID:4 nt.883-1319 XP002100510	1-8, 10-13, 15,20,21
Y	see the whole document ----	14,16-19
A	FÖRSTER R. ET AL.: "A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen" CELL, vol. 87, no. 6, 13 December 1996, pages 1037-1047, XP002100505 ----	
A	YOKOMIZO T. ET AL.: "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis" NATURE, vol. 387, 5 June 1997, pages 620-624, XP002100506 -----	

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/US 98/25565

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 18, 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
See FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-21 all partially

G-protein coupled receptor GRIR-1, comprising an aminoacid sequence as in Seq.ID:1 and variants. Polynucleotide encoding said GRIR-1, as in Seq.ID:2, variants, fragments, hybridizing sequences thereof. Expression vector containing said polynucleotide, host cell containing said vector. Method for producing said polypeptide. Pharmaceutical composition comprising said polypeptide. Antibodies, agonists, antagonists of said polypeptide. Application in therapy of said antagonist. Application in diagnostics of said polynucleotide.

2. Claims: 1-21 all partially

As invention 1 but concerning GRIR-2, as in Seq.ID:3 and 4.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Due to the large number of compounds falling under the terms "agonist" and "antagonist" of claims 16, 17 and all the claims referring to them, and due to the absence of any technical support for these compounds in the description, the search for said subject -matters was limited to peptides derived from the disclosed polypeptides, antibodies and antisense molecules.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/US 98/25565

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9639511	A 12-12-1996	AU	5972996 A	18-12-1996
		AU	6327396 A	24-12-1996
		CA	2220530 A	05-12-1996
		CA	2223038 A	12-12-1996
		EP	0832282 A	01-04-1998
		EP	0832231 A	01-04-1998
		WO	9638591 A	05-12-1996

